Skip to main content
PMC home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2005 Mar-Apr;20(2):91–96. doi: 10.1177/153331750502000208

Cholesterol and apolipoprotein E in Alzheimer's disease

Allison B Reiss 1
PMCID: PMC10833217  PMID: 15844755

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in North America and Europe. The incidence of the disease rises dramatically with age. AD is a complex multifactorial disorder that involves numerous susceptibility genes, but the exact pathogenesis and biochemical basis of AD is not well understood. Cholesterol is receiving a great deal of attention as a potentially crucial factor in the etiology of AD. Almost all cholesterol in the brain is synthesized in the brain. Cholesterol exits the brain through the blood-brain barrier (BBB) in the form of apolipoprotein E (ApoE) or by first being converted to a more polar compound, 24(S)-hydroxycholesterol, which is elevated in individuals with AD. The key event leading to AD appears to be the formation and aggregation in the brain of amyloid β (Aβ) peptide, a proteolytically derived product of amyloid precursor protein (APP). Cholesterol has been demonstrated to modulate processing of APP to Aβ. High levels of cholesterol are associated with increased risk of AD. Patients taking cholesterol-lowering statins have a lower prevalence of AD. ApoE, which transports cholesterol throughout the brain, exhibits an isoform-specific association with AD such that the E4 isoform, by unknown mechanisms, shifts the onset curve toward an earlier age.

Keywords: Alzheimer's disease, amyloid β peptide, apolipoprotein E, cholesterol

Full Text

The Full Text of this article is available as a PDF (80.4 KB).

References

  1. Clark C, Karlawish J: Alzheimer disease: Current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med. 2003; 138: 400-410. [DOI] [PubMed] [Google Scholar]
  2. Knopman D: Pharmacotherapy for Alzheimer's disease: 2002. Clinical Neuropharmacol. 2003; 26: 93-101. [DOI] [PubMed] [Google Scholar]
  3. Hardy J, Selkoe D: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002; 297: 353-356. [DOI] [PubMed] [Google Scholar]
  4. De Strooper B, Annaert W: Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000; 113:1857-1870. [DOI] [PubMed] [Google Scholar]
  5. Hartmann T: Cholesterol, A beta and Alzheimer's disease. Trend Neurosci. 2001; 24: S45-S48. [DOI] [PubMed] [Google Scholar]
  6. Launer L, White L, Petrovitch H, et al.: Cholesterol and neuropathologic markers of AD: A population-based autopsy study. Neurology. 2001; 57: 1447-1452. [DOI] [PubMed] [Google Scholar]
  7. Strittmatter W, Roses A: Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 4725-4727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Puglielli L, Tanzi R, Kovacs D: Alzheimer's disease: The cholesterol connection. Nat Neurosci. 2003; 6: 345-351. [DOI] [PubMed] [Google Scholar]
  9. Dietschy JM, Turley SD: Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001; 12: 105-112. [DOI] [PubMed] [Google Scholar]
  10. Björkhem I, Lütjohann D, Diczfalusy U, et al.: Cholesterol homeostasis in human brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res. 1998; 39: 1594-1600. [PubMed] [Google Scholar]
  11. Ballabh P, Braun A, Nedergaard M: The blood-brain barrier. An overview: Structure, regulation, and clinical implications. Neurobiol Dis. 2004; 16: 1-13. [DOI] [PubMed] [Google Scholar]
  12. Bjorkhem I, Meaney S: Brain cholesterol: Long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004; 24: 806-815. [DOI] [PubMed] [Google Scholar]
  13. Notkola I-L, Sulkava R, Pekkanen J, et al.: Serum total cholesterol, apolipoprotein E 4, and Alzheimer's disease. Neuroepidemiology. 1998; 17: 14-20. [DOI] [PubMed] [Google Scholar]
  14. Kivipelto M, Helkala E-L, Hänninen T, et al.: Midlife vascular risk factors and late-life mild cognitive impairment. A populationbased study. Neurology. 2001; 56: 1683-1689. [DOI] [PubMed] [Google Scholar]
  15. Wolozin B, Kellman W, Ruosseau P, et al.: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000; 57: 1439-1443. [DOI] [PubMed] [Google Scholar]
  16. Jick H, Zornberg G, Jick S, et al.: Statins and the risk of dementia. Lancet. 2000; 356: 1627-1631. [DOI] [PubMed] [Google Scholar]
  17. Fassbender K, Simons M, Bergmann C, et al.: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA. 2001; 98: 5856-5861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sparks D, Scheff S, Hunsaker J, et al.: Induction of Alzheimer like b-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exper Neurol. 1994; 126: 88-94. [DOI] [PubMed] [Google Scholar]
  19. Simons M, Keller P, De Strooper B, et al.: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 1998; 95: 6460-6464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Buxbaum J, Geoghagen N, Friedhoff L: Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alz Dis. 2001; 3: 221-229. [DOI] [PubMed] [Google Scholar]
  21. Refolo L, Malester B, LaFrancois J, et al.: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7: 321-331. [DOI] [PubMed] [Google Scholar]
  22. Bodovitz S, Klein W: Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996; 271: 4436-4440. [DOI] [PubMed] [Google Scholar]
  23. Fonarow G, Watson K: Effective strategies for long-term statin use. Am J Cardiol. 2003; 92(1A): 27i-34i. [DOI] [PubMed] [Google Scholar]
  24. Sjogren M, Gustafsson K, Syversen S, et al.: Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cog Dis. 2003; 16(1): 25-30. [DOI] [PubMed] [Google Scholar]
  25. Fassbender K, Stroik M, Bertsch T, et al.: Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002; 59: 1257-1258. [DOI] [PubMed] [Google Scholar]
  26. Vaughan C, Gotto A, Basson C: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000; 35: 1-10. [DOI] [PubMed] [Google Scholar]
  27. Stoll L, McCormick M, Denning G, et al.: Antioxidant effect of statins. Drugs Today. 2004; 40: 975-990. [DOI] [PubMed] [Google Scholar]
  28. Petanceska S, DeRosa S, Sharma A, et al.: Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Molec Neurosci. 2003; 20: 395-406. [DOI] [PubMed] [Google Scholar]
  29. Vega G, Weiner M, Lipton A, et al.: Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003; 60: 510-515. [DOI] [PubMed] [Google Scholar]
  30. Brown J, Theisler C, Silberman S, et al.: Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004; 279: 34674-34681. [DOI] [PubMed] [Google Scholar]
  31. Kirsch C, Eckert G, Koudinov A, et al.: Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry. 2003; 36 Suppl 2: S113-S119. [DOI] [PubMed] [Google Scholar]
  32. Lutjohann D, Stroick M, Bertsch T, et al.: High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids. 2004; 69: 431-438. [DOI] [PubMed] [Google Scholar]
  33. Lund E, Guileyardo J, Russell D: cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA. 1999; 96: 7238-7243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Bjorkhem I, Meaney S, Diczfalusy U: Oxysterols in human circulation: Which role do they have? Curr Opin Lipidol. 2002; 13: 247-253. [DOI] [PubMed] [Google Scholar]
  35. Lutjohann D, Papassotiropoulos A, Bjorkhem I, et al.: Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000; 41: 195-198. [PubMed] [Google Scholar]
  36. Papassotiropoulos A, Lutjohann D, Bagli M, et al.: Plasma 24S-hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport. 2000; 11:1959-1962. [DOI] [PubMed] [Google Scholar]
  37. Lutjohann D, von Bergmann K: 24S-hydroxycholesterol: A marker of brain cholesterol metabolism. Pharmacopsychiatry. 2003; 36 Suppl 2: S102-S106. [DOI] [PubMed] [Google Scholar]
  38. Wolozin B, Brown J, Theisler C, et al.: The cellular biochemistry of cholesterol and statins: Insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Review. 2004; 10: 127-146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Papassotiropoulos A, Streffer J, Tsolaki M, et al.: Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol. 2003; 60: 29-35. [DOI] [PubMed] [Google Scholar]
  40. Desai P, DeKosky S, Kamboh M: Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci Lett. 2002; 328: 9-12. [DOI] [PubMed] [Google Scholar]
  41. Kolsch H, Lutjohann D, Ludwig M, et al.: Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry. 2002; 7: 899-902. [DOI] [PubMed] [Google Scholar]
  42. Mahley R, Innerarity T, Rall S, et al.: Plasma lipoproteins: Apolipoprotein structure and function. J Lipid Res. 1984; 25: 1277-1294. [PubMed] [Google Scholar]
  43. Weisgraber K, Rall S, Mahley R: Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981; 256: 9077-9083. [PubMed] [Google Scholar]
  44. Breslow JL: Genetic basis of lipoprotein disorders. J Clin Invest. 1989; 84: 373-380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Herz J, Bock H: Lipoprotein receptors in the nervous system. Ann Rev Biochem. 2002; 71: 405-434. [DOI] [PubMed] [Google Scholar]
  46. Corder E, Saunders A, Strittmatter W, et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261: 921-923. [DOI] [PubMed] [Google Scholar]
  47. Roses A: Apolipoprotein E alleles as risk factors in Alzheimer's disease. Ann Rev Med. 1996; 47: 487-500. [DOI] [PubMed] [Google Scholar]
  48. Farrer L, Cupples L, Haines J, et al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278: 1349-1356. [PubMed] [Google Scholar]
  49. Schmechel DE, Saunders AM, Strittmatter WJ, et al.: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein-E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993; 90: 9649-9653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Breitner J, Wyse B, Anthony J, et al.: APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology. 1999; 53: 321-331. [DOI] [PubMed] [Google Scholar]
  51. Seshadri S, Drachman D, Lippa C: Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol. 1995; 52: 1074-1079. [DOI] [PubMed] [Google Scholar]
  52. Slooter A, Cruts M, Kalmijn S, et al.: Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch Neurol. 1998; 55: 964-968. [DOI] [PubMed] [Google Scholar]
  53. DeMattos R: Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J Molec Neurosci. 2004; 23: 255-262. [DOI] [PubMed] [Google Scholar]
  54. Ma J, Yee A, Brewer B, et al.: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature.1994; 372: 92-94. [DOI] [PubMed] [Google Scholar]
  55. Castano E, Prelli F, Wisniewski T, et al.: Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein. Eur Biochem J. 1995; 306: 599-604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Bales K, Verina T, Cummins D, et al.: Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 1999; 96: 15233-15238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. DeMattos R, Cirrito J, Parsadanian M, et al.: ApoE and clusterin cooperatively suppress Abeta levels and deposition. Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004; 41: 193-202. [DOI] [PubMed] [Google Scholar]
  58. Bazin H, Marques M, Owens A, et al.: Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. Biochemistry. 2002; 41: 8203-8211. [DOI] [PubMed] [Google Scholar]
  59. Judson R, Brain C, Dain B, et al.: New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis. 2004; 177: 345-351. [DOI] [PubMed] [Google Scholar]
  60. Marz W, Scharnagl H, Hoffmann M, et al.: The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J. 2004; 25: 2109-2119. [DOI] [PubMed] [Google Scholar]
  61. Yasojima K, Schwab C, McGeer EG, et al.: Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000; 887: 80-89. [DOI] [PubMed] [Google Scholar]
  62. Mahley R, Rall S: Apolipoprotein E: far more than a lipid transport protein. Ann Rev Genom Hum Genet. 2000; 1: 507-537. [DOI] [PubMed] [Google Scholar]
  63. Davignon J, Gregg R, Sing C: Apolipoprotein E polymorphism and arteriosclerosis. Arteriosclerosis. 1988; 8: 1-21. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES